Morningstar

Fresenius Medical Care Earnings: Progress Continues as External Pressures Ease

""
Securities In This Article
Fresenius Medical Care AG
(FME)

Narrow-moat Fresenius Medical Care FME turned in decent second-quarter results and increased its guidance for the full year. After tinkering with some of our near-term assumptions, we are keeping our EUR 67 per share fair value estimate unchanged and boosting the ADR fair value to $37 per share on foreign exchange rate changes since our last valuation update.

In the quarter, the dialysis business turned in results that were mildly higher than expected, as external challenges eased. For example, COVID-19 mortality challenges appear to be dissipating in the dialysis market as pandemic conditions ease, and labor challenges are dissipating in the U.S. market, too. Specifically, revenue grew 6% in constant currency, while adjusted EPS grew 54% in constant currency to EUR 0.59 per share, which was above FactSet consensus of EUR 0.52. The company also generated $854 million in free cash flow in the first half of the year, which was up 47% year over year.

Going forward, management still expects low- to mid-single-digit revenue growth in 2023, and considering recent trends, the company increased its target range for operating profit growth to a flat to mid-single-digit decline (versus flat to high-single-digit decline) for the full year. In the longer run, management still aims to boost adjusted operating margins to between 10% and 14% by 2025 from about 8% in the quarter, primarily by boosting its medical technology margins from a 1% level this quarter and executing on its ongoing cost-savings programs. Our fair value estimate only depends on the firm reaching the bottom end of that target range by 2025, so there could be upside to our fair value if the firm looks likely to make quicker or further progress on the margin front.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue

Estee Lauder, Kraft Heinz, and Dollar General are our top consumer defensive stocks.
Erin Lash, CFA

Industrials: Many Stocks Overvalued After Q3 Outperformance

Our top stocks in this sector are Chart Industries, Wesco, and CNH Industrial.
Brian Bernard, CFA, CPA

Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities

In this sector, our favored stocks are Albemarle, Dow, and FMC.
Andrew Bischof, CFA and Travis Miller

About the Author

Julie Utterback, CFA

Senior Equity Analyst
More from Author

Julie Utterback, CFA, is a senior equity analyst, AM Healthcare, for Morningstar*. She focuses on medical technology and service companies. She covers managed care organizations including UnitedHealth, service providers like HCA, medical suppliers such as Baxter, and life sciences companies like Danaher. She is also the chairperson of the equity research team’s capital allocation methodology.

Before joining Morningstar in 2005, Utterback was an equity analyst at State Farm Insurance for several years. Utterback joined Morningstar in 2005 as an equity analyst in the healthcare industry, and initially she primarily covered medical technology companies, including orthopedic device, medical equipment, and cardiac device firms. In 2010, she joined Morningstar's credit research team, initiating coverage of the entire healthcare industry and generally helping the organization expand and maintain its credit coverage across many industries. She held that senior credit analyst role until April 2019, when she returned to the equity team to cover medical technology and service companies.

Utterback holds a bachelor's degree in finance from the University of Illinois Urbana-Champaign’s Gies College of Business. She also holds the Chartered Financial Analyst® designation.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center